The complexity of choosing antihyperglycemic drugs to patients with COVID-19

• Alexander S. Ametov
• Alina P. Misharova

AbstractCoronavirus disease has corrected modern life. When someone with diabetes falls ill with COVID-19, a very severe case. Diabetes is accompanied by obesity, diseases of the cardiovascular system, kidneys. It adversely affect the outcome of an infectious disease. That is why, people with diabetes should control glycemia throughout the day and continue taking anti-hyperglycemic drugs. However, the question is openned that affects the new sugar-lowering drugs on the course of coronavirus infection.

Keywords:diabetes, antihyperglycemic drugs, glycemic control, corona virus disease

References

1. Kamkin E.G., Kostenko N.A., Karakulina E.A., et al. The provisional guidelines. Prevention, diagnosis and treatment of new coronavirus infection (COVID-19). Version 6 (28.04.2020): 5-8. (in Russian)

2. Ceriello A. Management of diabetes today: an exciting confusion. Diabetes Res Clin Pract. 2020; 162: 108129. DOI: 10.1016/j.dia-bres.2020.108129

3. Bhadada S.K. Should anti-diabetic medications be reconsidered amid COVID-19 pandemic? Diabetes Res Clin Pract. 2020. DOI: 10.1016/j. diabres.2020.108146

4. Fadini G.P., Morieri M.L., Longato E., Avogaro A. Prevalence and impact of diabetes among people infected with SARS-CoV-2. J Endocrinol Invest. 2020; 43 (6): 867-9. DOI: 10.1007/s40618-020-01236-2

5. Yang J., Zheng Y., Gou X., Pu K., Chen Z., Guo Q. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. Int J Infect Dis. 2020. DOI: 10.1016/j. ijid.2020.03.017

6. Grasselli G., Zangrillo A., Zanella A., Antonelli M., Cabrini L., Cas-telli A., et al. COVID-19 Lombardy ICU Network Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020; 323 (16): 1574-81. DOI: 10.1001/ jama.2020.5394

7. Guan W., et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020; 382: 1708-20. DOI: 10.1056/NE-JMoa2002032

8. Wu Z., McGoogan J.M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese center for disease control and prevention. JAMA. 2020; 323 (13): 1239-42.

9. Pal R., Bhansali A. COVID-19, diabetes mellitus and ACE 2: The conundrum. Diabetes Res Clin Pract. 2020; 162: 108132. DOI: 10.1016/j. diabres.2020.108132

10. Stoian A.P., Banerjee Y., Rizvi A.A., Rizzo M. Diabetes and the COVID-19 pandemic: how insights from recent experience might guide future management. Metab Syndr Relat Disord. 2020; 18 (4): 173-5. DOI: 10.1089/met.2020.0037

11. Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395 (10 229): 1054-62. DOI: 10.1016/S 0140-6736(20)30566-3

12. Prattichizzo F., La Sala L., Ryden L., Marx N., Ferrini M., Valensi P. Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases. Eur J Prev Cardiol. 2019; 26 (2 Suppl): 73-80. DOI: 10.1177/2047487319880040

13. He J., Yuan G., Cheng F., Zhang J., Guo X. Mast cell and M1 macrophage infiltration and local pro-inflammatory factors were attenuated with incretin-based therapies in obesity-related glomerulopathy. Metab Syndr Relat Disord. 2017; 15: 344-53. DOI: 10.1089/met.2017.0057

14. Amin E.F., Rifaai R.A., Abdel-Latif R.G. Empagliflozin attenuates transient cerebral ischemia/reperfusion injury in hyperglycemic rats via repressing oxidative-inflammatory-apoptotic pathway. Fundam Clin Pharmacol. 2020. DOI: 10.1111/fcp.12548

15. Ceriello A. Thiazolidinediones as anti-inflammatory and anti-atherogenic agents. Diabetes Metab Res Rev. 2008; 24: 14-26.

16. URL: https://www.ema.europa.eu/en/news/ema-advises-continued-use-medicines-hypertension-heart-kidney-disease-during-covid-19-pandemic.

17. Kajiwara C., Kusaka Y., Kimura S., Yamaguchi T., et al. Metformin mediates protection against Legionella pneumonia through activation of AMPK and mitochondrial reactive oxygen species. J Immunol. 2018; 200 (2): 623-31. DOI: 10.4049/jimmunol.1700474

18. Zhang M., He J.Q. Impacts of metformin on tuberculosis incidence and clinical outcomes in patients with diabetes: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2020; 76 (2): 149-59. DOI: 10.1007/ s00228-019-02786-y

19. Mendy A., Gopal R., Alcorn J.F., Forno E. Reduced mortality from lower respiratory tract disease in adult diabetic patients treated with metformin. Respirology. 2019; 24 (7): 646-51.

20. Ho T., Huang C., Tsai Y., et al. Metformin use mitigates the adverse prognostic effect of diabetes mellitus in chronic obstructive pulmonary disease. Respir Res. 2019; 20: 69. DOI: 10.1186/s12931-019-1035-9

21. Abouelkheir M., El-Metwally T.H. Dipeptidyl peptidase-4 inhibitors can inhibit angiotensin converting enzyme. Eur J Pharmacol. 2019; 862: 172638

22. Razavi Z., Maher S., Fredmal J. Comparison of subcutaneous insulin aspart and intravenous regular insulin for the treatment of mild and moderate diabetic ketoacidosis in pediatric patients. Endocrine. 2018; 61 (2): 26 7 - 74. URL: 10.1007/s12020-018-1635-z

23. Tran K.K., Kibert J.L. 2nd, Telford E.D., Franck A.J. Intravenous insulin infusion protocol compared with subcutaneous insulin for the management of hyperglycemia in critically ill adults. Ann Pharmacother. 2019; 53 (9): 894-8. DOI: 10.1177/106002801984136

24. Bhurayanontachai R., Rattanaprapat T., Kongkamol C. Comparison of glycemic control between continuous regular insulin infusion and single-dose subcutaneous insulin glargine injection in medical critically ill patients. Indian J Crit Care Med. 2018; 22 (3): 174-9. DOI: 10.4103/ijccm. IJCCM_273_17.

25. Lee S.W., Im R., Magbual R. Current perspectives on the use of continuous subcutaneous insulin infusion in the acute care setting and overview of therapy. Crit Care Nurs Q. 2004; 27 (2): 172-84.

26. Leelarathna L., English S.W., Thabit H., Caldwell K., et al. Feasibility of fully automated closed-loop glucose control using continuous subcutaneous glucose measurements in critical illness: a randomized controlled trial. Crit Care. 2013; 17 (4): R 159. DOI: 10.1186/cc12838

27. Yang J.K., Lin S.S., Ji X.J., Guo L.M. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol. 2010; 47 (3): 193-9. DOI: 10.1007/s00592-009-0109-4

28. Smith G.D., Amos T.A., Mahler R., Peters T.J. Effect of chloro-quine on insulin and glucose homoeostasis in normal subjects and patients with non-insulin-dependent diabetes mellitus. Br Med J. 1987; 294: 465-7.

29. Quatraro A., Consoli G., Magno M., Caretta F., Nardozza A., Ceri-ello A. Hydroxychloroquine in decompensated, treatment-refractory noninsulin-dependent diabetes mellitus. A new job for an old drug? Ann Intern Med. 1990; 112: 678-81.

30. Gentile S., Strollo F., Ceriello A. COVID-19 Infection in Italian people with diabetes: lessons learned for our future (an experience to be used). Diabetes Res Clin Pract. 2020. DOI: 10.1016/j.diabres.2020.108137

31. Hussain A., Bhowmik B., Cristina do Vale Moreira N. COVID-19 and diabetes: knowledge in progress. Diabetes Res Clin Pract. 2020; 162: 108142. DOI: 10.1016/j.diabres.2020.108142

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)